Tracked deals
24
24 tracked deals across 2014-2026.
Pharmaceuticals Buyers & Acquisitions in Massachusetts
Buyer mix
Strategic-led
21 strategic · 4 pe
Top trend
Volume peaked in 2023
9 tracked deals announced in 2023.
Primary Insight
What Stands Out
- Sanofi will acquire Blueprint Medicines to expand a rare immunology pipeline, with consideration that includes milestone payments tied to BLU-808.
- Novartis’s acquisition of Anthos Therapeutics and AbbVie’s acquisition of Cerevel Therapeutics reflect large-cap pipeline strategy in Massachusetts.
- Deal framing often blends upfront cash with CVRs (contingent value rights) in pharma-to-pharma transactions.
- Not all activity is full buyouts: NOF CORPORATION made a strategic minority investment in Phosphorex, a drug-delivery CDMO, to accelerate cGMP capabilities and support LNP-related collaboration.
- Commercial-stage repositioning appears in transactions like Zevra Therapeutics acquiring Acer Therapeutics, bringing an FDA-approved product into the buyer’s portfolio.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| AbbVie Inc. | 1 | Global biopharmaceutical company focused on developing an... | Strategic |
| Alcon Inc. | 1 | Global eye-care company offering surgical and vision-care... | Strategic |
| Assertio Holdings, Inc. | 1 | Specialty pharmaceutical company that commercializes diff... | Strategic |
| Azurity Pharmaceuticals | 1 | Privately held specialty pharmaceutical company focused o... | Strategic |
| B-FLEXION Life Sciences | 1 | Investment manager within the B-FLEXION group, focused on... | PE |
| Bristol Myers Squibb | 1 | Global biopharmaceutical company focused on discovering, ... | Strategic |
| Cambrex | 1 | Global contract development and manufacturing organizatio... | Strategic |
| Covis Group S.à r.l. | 1 | Private equity-backed global specialty pharmaceutical com... | PE |
| Gurnet Point Capital | 1 | Healthcare-focused private investment firm that invests i... | PE |
| Innoviva, Inc. | 1 | Diversified holding company with a portfolio of healthcar... | Strategic |
Acquisition Volume in Pharmaceuticals in Massachusetts by Year
Last 8 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
January 12, 2026
- Buyer
- B-FLEXION Life Sciences
- Target
- Radius Health
- Seller
- Affiliates of Patient Square Capital, Webster Equity Partners
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.
-
November 17, 2025
- Buyer
- Azurity Pharmaceuticals
- Target
- Sebela Pharmaceuticals' Bowel Prep Franchise
- Seller
- Sebela Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Azurity Pharmaceuticals has acquired Sebela Pharmaceuticals' bowel preparation franchise, including two leading bowel prep therapies used for colonoscopies. The deal transfers Sebela's commercial team (more than 50 colleagues) and is intended to strengthen Azurity's gastroenterology product portfolio and U.S. market presence.
-
- Buyer
- Sanofi
- Target
- Blueprint Medicines Corporation
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.
-
February 11, 2025
- Buyer
- Novartis
- Target
- Anthos Therapeutics, Inc., Anthos Therapeutics
- Seller
- Anthos Therapeutics shareholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.
-
- Buyer
- NOF CORPORATION
- Target
- Phosphorex
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Growth capital
Japanese chemical manufacturer NOF Corporation completed a strategic minority investment in Phosphorex, a Hopkinton, Massachusetts-based drug-delivery CDMO backed by Ampersand Capital Partners. The investment will fund acceleration of Phosphorex's cGMP capabilities and strengthen collaboration on lipid nanoparticle (LNP) technologies and NOF's COATSOME SS series ionizable lipids.
-
June 12, 2024
- Buyer
- Ono Pharmaceutical Co., Ltd., Topaz Merger Sub Inc.
- Target
- Deciphera Pharmaceuticals Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Ono Pharmaceutical Co., Ltd. completed its previously announced tender offer to acquire all outstanding shares of Deciphera Pharmaceuticals Inc. for $25.60 per share, totaling approximately $2.4 billion. Following the tender offer, a wholly-owned subsidiary merged with and into Deciphera, with Deciphera surviving as a wholly owned subsidiary of Ono.
-
December 22, 2023
- Buyer
- Bristol Myers Squibb
- Target
- Karuna Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Bristol Myers Squibb (BMS) and Karuna Therapeutics entered into a definitive merger agreement under which BMS will acquire Karuna for $330 per share in cash, valuing Karuna’s equity at about $14.0 billion (about $12.7 billion net of estimated cash acquired). The deal is expected to close in the first half of 2024, subject to customary approvals and regulatory conditions.
-
December 6, 2023
- Buyer
- AbbVie Inc.
- Target
- Cerevel Therapeutics
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.
-
November 20, 2023
- Buyer
- Zevra Therapeutics, Inc.
- Target
- Acer Therapeutics, Inc.
- Seller
- Acer Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.
-
September 21, 2023
- Buyer
- Gurnet Point Capital, Novo Holdings A/S
- Target
- Paratek Pharmaceuticals, Inc.
- Seller
- Paratek Pharmaceuticals stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.
-
August 1, 2023
- Buyer
- Revolution Medicines, Inc.
- Target
- EQRx, Inc.
- Seller
- EQRx stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Revolution Medicines (NASDAQ: RVMD) has agreed to acquire EQRx (NASDAQ: EQRX) in an all‑stock transaction that will transfer more than $1 billion in net cash to Revolution’s balance sheet. The deal is intended to strengthen Revolution Medicines’ financial position to accelerate clinical development of its RAS(ON) inhibitor pipeline while EQRx will wind down most of its R&D programs post-closing.
-
April 25, 2023
- Buyer
- Assertio Holdings, Inc.
- Target
- Spectrum Pharmaceuticals, Inc.
- Seller
- Spectrum stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.
-
- Buyer
- Takeda Pharmaceutical Company Limited
- Target
- Nimbus Lakshmi, Inc.
- Seller
- Nimbus Therapeutics, LLC
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.
-
January 20, 2023
- Buyer
- LG Chem, Ltd.
- Target
- AVEO Oncology
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
LG Chem completed its all-cash acquisition of AVEO Oncology for an implied equity value of $571 million, making AVEO a wholly owned subsidiary of LG Chem Life Sciences Innovation Center. The deal expands LG Chem’s oncology capabilities and commercial footprint in the United States while positioning AVEO to leverage LG Chem’s R&D and manufacturing resources to advance its oncology pipeline and commercialization efforts.
-
January 18, 2023
- Buyer
- Cambrex
- Target
- Snapdragon Chemistry
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Cambrex has acquired Snapdragon Chemistry, a Waltham, Massachusetts-based specialist in API batch and continuous flow process development. The deal brings Snapdragon's ~70–75 scientists and engineers (including 31 PhDs) and continuous flow capabilities into Cambrex's global CDMO platform to expand its process development and manufacturing offerings.
-
August 12, 2022
- Buyer
- Ipsen
- Target
- Epizyme, Inc. (Epizyme)
- Seller
- Royalty Pharma (support agreement; agreed to tender shares)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.
-
July 11, 2022
- Buyer
- Innoviva, Inc., Innoviva (wholly owned subsidiary)
- Target
- La Jolla Pharmaceutical Company
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.
-
- Buyer
- Alcon Inc.
- Target
- Kala Pharmaceuticals, Inc.
- Seller
- Kala Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.
-
- Buyer
- Taiho Pharmaceutical Co., Ltd.
- Target
- Cullinan Pearl Corp.
- Seller
- Cullinan Oncology, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Taiho Pharmaceutical Co., Ltd. will acquire Cullinan Pearl Corp., a subsidiary of Cullinan Oncology, for $275 million upfront plus up to $130 million in regulatory milestone payments, and will co-develop and co-commercialize CLN-081/TAS6417. Cullinan Oncology will retain co-development and an option to co-commercialize in the U.S.; the deal provides Cullinan Oncology with cash to extend its runway and reduces its development and pre-commercialization costs.
-
November 11, 2021
- Buyer
- Pharmacosmos A/S
- Target
- AbFero Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.
-
October 11, 2021
- Buyer
- Pacira BioSciences, Inc.
- Target
- Flexion Therapeutics, Inc.
- Seller
- Flexion Therapeutics stockholders, Flexion directors and executive officers (and affiliates)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash plus one contingent value right (CVR) worth up to $8.00 per share tied to sales and regulatory milestones. The deal adds Flexion's marketed non-opioid OA knee pain therapy ZILRETTA and its clinical-stage pipeline to Pacira's non-opioid pain management portfolio; the transaction was expected to close in Q4 2021 and to be accretive to Pacira's earnings.
-
November 16, 2020
- Buyer
- Covis Group S.à r.l.
- Target
- AMAG Pharmaceuticals, Inc.
- Seller
- Public shareholders of AMAG Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Covis Group S.à r.l. completed a cash tender offer and merger to acquire AMAG Pharmaceuticals, Inc. for $13.75 per share, taking AMAG private and delisting its NASDAQ shares. The acquisition adds AMAG’s marketed products (including Feraheme and Makena) and development-stage assets in women’s health and hematology/oncology to Covis’ specialty pharma portfolio, supported by financing from Capital One and investment funds managed by HPS Investment Partners.
-
June 28, 2018
- Buyer
- Novacap
- Target
- PCI Synthesis
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.
-
July 2, 2014
- Buyer
- Nicox S.A.
- Target
- Aciex Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Frequently Asked Questions
Which major pharma buyers appear in Massachusetts pharmaceuticals acquisitions?
The page lists Sanofi, Novartis, Bristol Myers Squibb, and AbbVie among the recurring acquirers, alongside other platform and investment buyers.
Do these deals in Massachusetts include contingent value rights (CVRs)?
Yes. Multiple acquisitions are described as including CVRs or contingent payments, including transactions involving Azurity Pharmaceuticals, Zevra Therapeutics, Gurnet Point Capital/Novo Holdings, and Assertio Holdings.
Are there acquisitions that focus on product franchises rather than full pipeline buildouts?
Yes. Azurity Pharmaceuticals acquired Sebela Pharmaceuticals’ Bowel Prep Franchise, including bowel preparation therapies used for colonoscopies.
Are there any non-acquisition investments shown in Massachusetts?
Yes. NOF CORPORATION completed a strategic minority investment in Phosphorex to fund acceleration of cGMP capabilities and support collaboration around lipid nanoparticle (LNP) technologies.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2025
Pharmaceuticals Acquisitions in 2024
Pharmaceuticals Acquisitions in 2023
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2021
Acquisitions in Massachusetts
Private Equity-Backed Acquisitions in Massachusetts
Acquisitions in Massachusetts in 2026